Psoriatic arthritis

Oliver FitzGerald; Alexis Ogdie; Vinod Chandran; Laura C. Coates; Arthur Kavanaugh; William Tillett; Ying Ying Leung; Maarten deWit; Jose U. Scher; Philip J. Mease

doi:10.1038/s41572-021-00293-y

Psoriatic arthritis

Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, Laura C. Coates, Arthur Kavanaugh, William Tillett, Ying Ying Leung, Maarten deWit, Jose U. Scher, Philip J. Mease

Research output: Contribution to journal › Review article › peer-review

195 Citations (SciVal)

774 Downloads (Pure)

Abstract

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests available. Diagnosis is most commonly made by identifying inflammatory musculoskeletal features in joints, entheses or the spine in the presence of skin and/or nail psoriasis and in the usual absence of rheumatoid factor and anti-cyclic citrullinated peptide. The evolution of psoriasis to PsA may occur in stages, although the mechanisms are unclear. In many patients, there may be little or no relationship between severity of musculoskeletal inflammation and severity of skin or nail psoriasis. The reason for this disease heterogeneity may be explained by differences in genotype, especially in the HLA region. New targeted therapies for PsA have been approved with additional therapies in development. These developments have substantially improved both short-term and long-term outcomes including a reduction in musculoskeletal and skin manifestations and in radiographic damage. With efforts underway aimed at improving our understanding of the molecular basis for the heterogeneity of PsA, a personalized approach to treating PsA may become possible.

Original language	English
Article number	59
Journal	Nature Reviews Disease Primers
Volume	7
Issue number	1
Early online date	12 Aug 2021
DOIs	https://doi.org/10.1038/s41572-021-00293-y
Publication status	Published - 12 Aug 2021

Bibliographical note

Funding Information:
O.F. has received research grants and/or consulting fees from AbbVie, Amgen, Bristol Myers Squibb (BMS), Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc. and UCB. A.O. has consulted for AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB, and has received grants from Novartis and Pfizer. Her husband has received royalties from Novartis. V.C. reports grants and personal fees from Amgen, grants and personal fees from AbbVie, grants and personal fees from (and other potential interest (spouse employment) in) Eli Lilly and personal fees from BMS, Janssen, Novartis, Pfizer and UCB, outside the submitted work. L.C.C. is a recipient of research funds from AbbVie, Amgen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. She has received consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Domain, Gilead, Janssen, Lilly, Novartis, Pfizer, Serac and UCB. She reports reimbursement for attending a symposium from Janssen and AbbVie, and fees for organizing education from UCB. She has received fees for speaking and hospitality from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. A.K. conducted clinical trials sponsored by and/or consulted for Amgen, AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB. W.T. has received research grants, and consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB. Y.Y.L. is supported by the National Medical Research Council, Singapore. She has received honoraria from Janssen, AbbVie, Novartis and DKSH. M.deW. has received fees for lectures or consultancy through Stichting Tools from Celgene, Eli Lilly, Pfizer and UCB. J.U.S. has received funding for investigator-initiated studies from Novartis and Janssen and has served as a consultant for Janssen, Novartis, Pfizer, Lilly, AbbVie, Sanofi and UCB. P. J. M. has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun and UCB. He acts as a consultant with AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun and UCB. He has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB.

Funding Information:
V.C. acknowledges support of the Pfizer Chair Rheumatology Research Award from the Department of Medicine, University of Toronto. L.C.C. is an NIHR Clinician Scientist funded by a National Institute for Health Research Clinician Scientist award. The research was supported by the National Institute for Health Research (NIHR) and the Oxford Biomedical Research Centre (BRC). Y.Y.L. is supported by National Medical Research Council, Singapore.

Publisher Copyright:
© 2021, Springer Nature Limited.

Funding

O.F. has received research grants and/or consulting fees from AbbVie, Amgen, Bristol Myers Squibb (BMS), Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc. and UCB. A.O. has consulted for AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB, and has received grants from Novartis and Pfizer. Her husband has received royalties from Novartis. V.C. reports grants and personal fees from Amgen, grants and personal fees from AbbVie, grants and personal fees from (and other potential interest (spouse employment) in) Eli Lilly and personal fees from BMS, Janssen, Novartis, Pfizer and UCB, outside the submitted work. L.C.C. is a recipient of research funds from AbbVie, Amgen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. She has received consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Domain, Gilead, Janssen, Lilly, Novartis, Pfizer, Serac and UCB. She reports reimbursement for attending a symposium from Janssen and AbbVie, and fees for organizing education from UCB. She has received fees for speaking and hospitality from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. A.K. conducted clinical trials sponsored by and/or consulted for Amgen, AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB. W.T. has received research grants, and consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB. Y.Y.L. is supported by the National Medical Research Council, Singapore. She has received honoraria from Janssen, AbbVie, Novartis and DKSH. M.deW. has received fees for lectures or consultancy through Stichting Tools from Celgene, Eli Lilly, Pfizer and UCB. J.U.S. has received funding for investigator-initiated studies from Novartis and Janssen and has served as a consultant for Janssen, Novartis, Pfizer, Lilly, AbbVie, Sanofi and UCB. P. J. M. has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun and UCB. He acts as a consultant with AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun and UCB. He has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB. V.C. acknowledges support of the Pfizer Chair Rheumatology Research Award from the Department of Medicine, University of Toronto. L.C.C. is an NIHR Clinician Scientist funded by a National Institute for Health Research Clinician Scientist award. The research was supported by the National Institute for Health Research (NIHR) and the Oxford Biomedical Research Centre (BRC). Y.Y.L. is supported by National Medical Research Council, Singapore.

ASJC Scopus subject areas

General Medicine

Access to Document

10.1038/s41572-021-00293-y

PSA_v1_for_PR_1620656003_63.OF_1_ (1)PDF
This is a post-peer-review, pre-copyedit version of an article published in Nature Reviews Disease Primers. The final authenticated version is available online at: https://doi.org/s41572-021-00293-y
Accepted author manuscript, 682 KB

Cite this

@article{0b4e6ee86d9a4b3cabf0d2cf023cb80e,

title = "Psoriatic arthritis",

abstract = "Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests available. Diagnosis is most commonly made by identifying inflammatory musculoskeletal features in joints, entheses or the spine in the presence of skin and/or nail psoriasis and in the usual absence of rheumatoid factor and anti-cyclic citrullinated peptide. The evolution of psoriasis to PsA may occur in stages, although the mechanisms are unclear. In many patients, there may be little or no relationship between severity of musculoskeletal inflammation and severity of skin or nail psoriasis. The reason for this disease heterogeneity may be explained by differences in genotype, especially in the HLA region. New targeted therapies for PsA have been approved with additional therapies in development. These developments have substantially improved both short-term and long-term outcomes including a reduction in musculoskeletal and skin manifestations and in radiographic damage. With efforts underway aimed at improving our understanding of the molecular basis for the heterogeneity of PsA, a personalized approach to treating PsA may become possible.",

author = "Oliver FitzGerald and Alexis Ogdie and Vinod Chandran and Coates, {Laura C.} and Arthur Kavanaugh and William Tillett and Leung, {Ying Ying} and Maarten deWit and Scher, {Jose U.} and Mease, {Philip J.}",

note = "Funding Information: O.F. has received research grants and/or consulting fees from AbbVie, Amgen, Bristol Myers Squibb (BMS), Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc. and UCB. A.O. has consulted for AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB, and has received grants from Novartis and Pfizer. Her husband has received royalties from Novartis. V.C. reports grants and personal fees from Amgen, grants and personal fees from AbbVie, grants and personal fees from (and other potential interest (spouse employment) in) Eli Lilly and personal fees from BMS, Janssen, Novartis, Pfizer and UCB, outside the submitted work. L.C.C. is a recipient of research funds from AbbVie, Amgen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. She has received consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Domain, Gilead, Janssen, Lilly, Novartis, Pfizer, Serac and UCB. She reports reimbursement for attending a symposium from Janssen and AbbVie, and fees for organizing education from UCB. She has received fees for speaking and hospitality from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. A.K. conducted clinical trials sponsored by and/or consulted for Amgen, AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB. W.T. has received research grants, and consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB. Y.Y.L. is supported by the National Medical Research Council, Singapore. She has received honoraria from Janssen, AbbVie, Novartis and DKSH. M.deW. has received fees for lectures or consultancy through Stichting Tools from Celgene, Eli Lilly, Pfizer and UCB. J.U.S. has received funding for investigator-initiated studies from Novartis and Janssen and has served as a consultant for Janssen, Novartis, Pfizer, Lilly, AbbVie, Sanofi and UCB. P. J. M. has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun and UCB. He acts as a consultant with AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun and UCB. He has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB. Funding Information: V.C. acknowledges support of the Pfizer Chair Rheumatology Research Award from the Department of Medicine, University of Toronto. L.C.C. is an NIHR Clinician Scientist funded by a National Institute for Health Research Clinician Scientist award. The research was supported by the National Institute for Health Research (NIHR) and the Oxford Biomedical Research Centre (BRC). Y.Y.L. is supported by National Medical Research Council, Singapore. Publisher Copyright: {\textcopyright} 2021, Springer Nature Limited.",

year = "2021",

month = aug,

day = "12",

doi = "10.1038/s41572-021-00293-y",

language = "English",

volume = "7",

journal = "Nature Reviews Disease Primers",

issn = "2056-676X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Psoriatic arthritis

AU - FitzGerald, Oliver

AU - Ogdie, Alexis

AU - Chandran, Vinod

AU - Coates, Laura C.

AU - Kavanaugh, Arthur

AU - Tillett, William

AU - Leung, Ying Ying

AU - deWit, Maarten

AU - Scher, Jose U.

AU - Mease, Philip J.

N1 - Funding Information: O.F. has received research grants and/or consulting fees from AbbVie, Amgen, Bristol Myers Squibb (BMS), Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc. and UCB. A.O. has consulted for AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB, and has received grants from Novartis and Pfizer. Her husband has received royalties from Novartis. V.C. reports grants and personal fees from Amgen, grants and personal fees from AbbVie, grants and personal fees from (and other potential interest (spouse employment) in) Eli Lilly and personal fees from BMS, Janssen, Novartis, Pfizer and UCB, outside the submitted work. L.C.C. is a recipient of research funds from AbbVie, Amgen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. She has received consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Domain, Gilead, Janssen, Lilly, Novartis, Pfizer, Serac and UCB. She reports reimbursement for attending a symposium from Janssen and AbbVie, and fees for organizing education from UCB. She has received fees for speaking and hospitality from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. A.K. conducted clinical trials sponsored by and/or consulted for Amgen, AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB. W.T. has received research grants, and consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB. Y.Y.L. is supported by the National Medical Research Council, Singapore. She has received honoraria from Janssen, AbbVie, Novartis and DKSH. M.deW. has received fees for lectures or consultancy through Stichting Tools from Celgene, Eli Lilly, Pfizer and UCB. J.U.S. has received funding for investigator-initiated studies from Novartis and Janssen and has served as a consultant for Janssen, Novartis, Pfizer, Lilly, AbbVie, Sanofi and UCB. P. J. M. has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun and UCB. He acts as a consultant with AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun and UCB. He has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB. Funding Information: V.C. acknowledges support of the Pfizer Chair Rheumatology Research Award from the Department of Medicine, University of Toronto. L.C.C. is an NIHR Clinician Scientist funded by a National Institute for Health Research Clinician Scientist award. The research was supported by the National Institute for Health Research (NIHR) and the Oxford Biomedical Research Centre (BRC). Y.Y.L. is supported by National Medical Research Council, Singapore. Publisher Copyright: © 2021, Springer Nature Limited.

PY - 2021/8/12

Y1 - 2021/8/12

N2 - Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests available. Diagnosis is most commonly made by identifying inflammatory musculoskeletal features in joints, entheses or the spine in the presence of skin and/or nail psoriasis and in the usual absence of rheumatoid factor and anti-cyclic citrullinated peptide. The evolution of psoriasis to PsA may occur in stages, although the mechanisms are unclear. In many patients, there may be little or no relationship between severity of musculoskeletal inflammation and severity of skin or nail psoriasis. The reason for this disease heterogeneity may be explained by differences in genotype, especially in the HLA region. New targeted therapies for PsA have been approved with additional therapies in development. These developments have substantially improved both short-term and long-term outcomes including a reduction in musculoskeletal and skin manifestations and in radiographic damage. With efforts underway aimed at improving our understanding of the molecular basis for the heterogeneity of PsA, a personalized approach to treating PsA may become possible.

AB - Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests available. Diagnosis is most commonly made by identifying inflammatory musculoskeletal features in joints, entheses or the spine in the presence of skin and/or nail psoriasis and in the usual absence of rheumatoid factor and anti-cyclic citrullinated peptide. The evolution of psoriasis to PsA may occur in stages, although the mechanisms are unclear. In many patients, there may be little or no relationship between severity of musculoskeletal inflammation and severity of skin or nail psoriasis. The reason for this disease heterogeneity may be explained by differences in genotype, especially in the HLA region. New targeted therapies for PsA have been approved with additional therapies in development. These developments have substantially improved both short-term and long-term outcomes including a reduction in musculoskeletal and skin manifestations and in radiographic damage. With efforts underway aimed at improving our understanding of the molecular basis for the heterogeneity of PsA, a personalized approach to treating PsA may become possible.

UR - http://www.scopus.com/inward/record.url?scp=85112697594&partnerID=8YFLogxK

U2 - 10.1038/s41572-021-00293-y

DO - 10.1038/s41572-021-00293-y

M3 - Review article

AN - SCOPUS:85112697594

SN - 2056-676X

VL - 7

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

IS - 1

M1 - 59

ER -

Psoriatic arthritis

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this

Psoriatic arthritis

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Projects

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this